Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (884)	2/28/1999 2:43:00 PM
From: rkrw	Respond to of 887

<<I'm puzzled how they will ever get to profitability.>> Paxil SR royalties for starters. I responded to your post which stated that you intended to vote against the merger pending further review. I stated a few reasons why I'm in favor of the merger. Frankly, I am puzzled that you can read the proxy yet remain at the same conclusion. BTW: The short shares you cite are arbitrage and the ratio you include is very misleading given Skye primarily trades on the London Exchange, not Nasdaq. Further, your assumptions regarding debenture holders actions do not necessarily apply to European investors.